GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pliant Therapeutics Inc (NAS:PLRX) » Definitions » EPS without NRI

Pliant Therapeutics (Pliant Therapeutics) EPS without NRI

: $-2.76 (TTM As of Dec. 2023)
View and export this data going back to 2020. Start your Free Trial

Pliant Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.69. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.76.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -12.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -56.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Pliant Therapeutics's EPS without NRI or its related term are showing as below:

PLRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -371.8   Med: -12.1   Max: -8.4
Current: -12.1

During the past 6 years, Pliant Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -8.40% per year. The lowest was -371.80% per year. And the median was -12.10% per year.

PLRX's 3-Year EPS without NRI Growth Rate is ranked worse than
69.39% of 1297 companies
in the Biotechnology industry
Industry Median: 4.5 vs PLRX: -12.10

Pliant Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.76.

Pliant Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-0.69. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.76.


Pliant Therapeutics EPS without NRI Historical Data

The historical data trend for Pliant Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Premium Member Only -0.03 -1.95 -2.71 -2.94 -2.75

Pliant Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.72 -0.67 -0.70 -0.70 -0.69

Competitive Comparison

For the Biotechnology subindustry, Pliant Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pliant Therapeutics PE Ratio without NRI Distribution

For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Pliant Therapeutics's PE Ratio without NRI falls into.



Pliant Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pliant Therapeutics  (NAS:PLRX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pliant Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Pliant Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Pliant Therapeutics (Pliant Therapeutics) Business Description

Traded in Other Exchanges
Address
260 Littlefield Avenue, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Executives
Hans Hull officer: Chief Business Officer C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Eric Lefebvre officer: Chief Medical Officer C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Keith Lamont Cummings officer: Chief Financial Officer C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Bernard Coulie director, officer: President and CEO C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Mike Ouimette officer: General Counsel C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lily Cheung officer: Chief Human Resource Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Kevin P Starr 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Smital Shah director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129

Pliant Therapeutics (Pliant Therapeutics) Headlines

From GuruFocus

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

By Stock market mentor Stock market mentor 01-23-2023

Pliant Therapeutics to Participate in Upcoming Investor Events

By Stock market mentor Stock market mentor 02-07-2023